NASDAQ: PGNYProgyny Inc Stock
$28.51+1.13 (+4.13%)
Updated Jun 26, 2026
PGNY Price
$28.51
Fair Value Price
$74.25
Market Cap
$2.23B
52 Week Low
$16.10
52 Week High
$28.75
P/E
35.64x
P/B
5.08x
P/S
1.06x
PEG
1.27x
Dividend Yield
N/A
Revenue
$1.29B
Earnings
$67.69M
Gross Margin
24.1%
Operating Margin
8.18%
Profit Margin
5.2%
Debt to Equity
0.59
Operating Cash Flow
$206M
Beta
1.04
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PGNY Overview
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PGNY's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
C
PGNY
Ranked#3 of 43
Ranked#3 of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $40.13 | A | |
| $68.98 | A | |
| $5.12 | B |
Be the first to know about important PGNY news, forecast changes, insider trades & much more!
PGNY News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PGNY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PGNY ($28.51) is undervalued by 61.6% relative to our estimate of its Fair Value price of $74.25 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PGNY ($28.51) is significantly undervalued by 61.6% relative to our estimate of its Fair Value price of $74.25 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PGNY ($28.51) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PGNY due diligence checks available for Premium users.
Valuation
PGNY fair value
Fair Value of PGNY stock based on Discounted Cash Flow (DCF)
Price
$28.51
Fair Value
$74.25
Undervalued by
61.60%
PGNY ($28.51) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PGNY ($28.51) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PGNY ($28.51) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PGNY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
35.64x
Industry
12.84x
Market
12.38x
PGNY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PGNY is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
PGNY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.08x
Industry
3.28x
PGNY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PGNY price to earnings growth (PEG)
For valuing profitable companies with growth potential
PGNY is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
PGNY's financial health
Profit margin
Revenue
$328.5M
Net Income
$24.2M
Profit Margin
7.4%
PGNY's Earnings (EBIT) of $105.78M... subscribe to Premium to read more.
Interest Coverage Financials
PGNY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$698.3M
Liabilities
$259.0M
Debt to equity
0.59
PGNY's short-term assets ($501.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PGNY's short-term assets ($501.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PGNY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PGNY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$45.9M
Investing
$96.6M
Financing
-$123.1M
PGNY's operating cash flow ($206.33M)... subscribe to Premium to read more.
Debt Coverage Financials
PGNY vs Health Information Service Stocks
Progyny Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.